Ultragenyx Pharmaceutical (NASDAQ:RARE) Upgraded to “Hold” at BidaskClub

BidaskClub upgraded shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) from a sell rating to a hold rating in a research note published on Tuesday, BidAskClub reports.

Other equities research analysts have also recently issued research reports about the stock. Wedbush reaffirmed a buy rating and issued a $75.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Thursday, August 15th. Barclays reiterated a buy rating and set a $87.00 price target on shares of Ultragenyx Pharmaceutical in a report on Sunday, August 4th. Morgan Stanley lowered their price target on shares of Ultragenyx Pharmaceutical from $83.00 to $79.00 and set an overweight rating for the company in a report on Friday, August 2nd. ValuEngine upgraded shares of Ultragenyx Pharmaceutical from a hold rating to a buy rating in a report on Wednesday, October 2nd. Finally, Piper Jaffray Companies set a $75.00 price target on shares of Ultragenyx Pharmaceutical and gave the company a buy rating in a report on Wednesday, September 4th. Three investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The company presently has an average rating of Buy and a consensus price target of $74.23.

Shares of Ultragenyx Pharmaceutical stock opened at $43.26 on Tuesday. Ultragenyx Pharmaceutical has a 52-week low of $37.44 and a 52-week high of $75.72. The stock has a market capitalization of $2.50 billion, a price-to-earnings ratio of -5.85 and a beta of 2.12. The company has a fifty day moving average of $47.45 and a 200-day moving average of $58.87. The company has a debt-to-equity ratio of 0.04, a quick ratio of 9.14 and a current ratio of 9.32.



Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.72) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.73) by $0.01. Ultragenyx Pharmaceutical had a negative net margin of 527.49% and a negative return on equity of 49.84%. The company had revenue of $24.15 million during the quarter, compared to analysts’ expectations of $22.16 million. During the same quarter in the prior year, the company earned ($1.06) EPS. The firm’s revenue was up 88.8% on a year-over-year basis. On average, equities research analysts forecast that Ultragenyx Pharmaceutical will post -7.05 earnings per share for the current fiscal year.

In other news, CEO Emil D. Kakkis purchased 5,000 shares of the stock in a transaction that occurred on Wednesday, September 11th. The stock was bought at an average cost of $43.63 per share, for a total transaction of $218,150.00. Following the acquisition, the chief executive officer now directly owns 472,479 shares of the company’s stock, valued at approximately $20,614,258.77. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 7.80% of the company’s stock.

A number of large investors have recently bought and sold shares of RARE. Vanguard Group Inc. raised its holdings in Ultragenyx Pharmaceutical by 2.3% in the 2nd quarter. Vanguard Group Inc. now owns 5,005,872 shares of the biopharmaceutical company’s stock worth $317,874,000 after purchasing an additional 112,101 shares in the last quarter. BlackRock Inc. raised its holdings in Ultragenyx Pharmaceutical by 6.0% in the 1st quarter. BlackRock Inc. now owns 4,745,363 shares of the biopharmaceutical company’s stock worth $329,138,000 after purchasing an additional 268,551 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Ultragenyx Pharmaceutical by 31.7% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 4,611,939 shares of the biopharmaceutical company’s stock worth $292,858,000 after purchasing an additional 1,110,316 shares in the last quarter. First Trust Advisors LP raised its holdings in Ultragenyx Pharmaceutical by 26.3% in the 1st quarter. First Trust Advisors LP now owns 1,859,052 shares of the biopharmaceutical company’s stock worth $128,944,000 after purchasing an additional 387,118 shares in the last quarter. Finally, Clearbridge Investments LLC raised its holdings in Ultragenyx Pharmaceutical by 0.3% in the 1st quarter. Clearbridge Investments LLC now owns 1,013,273 shares of the biopharmaceutical company’s stock worth $70,281,000 after purchasing an additional 3,237 shares in the last quarter.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.

See Also: What is a stock split?

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.